原发性胆汁性胆管炎:机遇与挑战

王绮夏; 马雄

doi:10.3969/j.issn.1001-5256.2017.11.001

原发性胆汁性胆管炎:机遇与挑战

DOI: 10.3969/j.issn.1001-5256.2017.11.001

王绮夏,
马雄

上海交通大学医学院附属仁济医院消化内科上海市消化疾病研究所

基金项目:

国家杰出青年科学基金(81325002)；国家自然科学基金国际合作与交流项目(81620108002);国家自然科学基金面上项目(81570511,81770564)；上海市卫生计生系统“优秀青年医学人才培养计划”(2017YQ037)；

详细信息

中图分类号: R575.22
计量
- 文章访问数: 368
- HTML全文浏览量: 25
- PDF下载量: 276
- 被引次数: 0
出版历程
- 收稿日期: 2017-10-11
- 出版日期: 2017-11-20

Primary biliary cholangitis:opportunities and challenges

Department of Gastroenterology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai Institute of Digestive Disease

Research funding:

摘要

摘要: 原发性胆汁性胆管炎是一种累及肝小叶间胆管的自身免疫性肝病,可进展为肝硬化、肝功能衰竭。早期诊断和治疗可显著改善患者预后,提高生活质量。将2017年欧洲肝病学会《原发性胆汁性胆管炎临床实践指南》与实际临床经验相结合,重点评述我国原发性胆汁性胆管炎研究取得的进展和遇到的难点问题。
- 胆管炎,胆汁性 /
- 诊断 /
- 治疗 /
- 述评
Abstract: Primary biliary cholangitis (PBC) is an autoimmune liver disease mainly involving the interlobular bile ducts and can progress to liver cirrhosis and liver failure.Early diagnosis and management can significantly improve the prognosis of such patients and their quality of life.This article focuses on the achievements of PBC research and related difficult issues in China, with reference to the clinical practice guidelines for PBC by European Association for the Study of the Liver in 2017 and experience in clinical practice.
- cholangitis, biliary /
- diagnosis /
- therapy /
- editorial

HTML全文

参考文献(13)

[1]BEUERS U, GERSHWIN ME, GISH RG, et al.Changing nomenclature for PBC:from cirrhosis to cholangitis[J].J Hepatol, 2015, 13 (11) :1867-1869.

[2]SHUAI Z, WANG J, BADAMAGUNTA M, et al.The fingerprint of antimitochondrial antibodies and the etiology of primary biliary cholangitis[J].Hepatology, 2017, 65 (5) :1670-1682.

[3]European Association for the Study of the Liver.EASL clinical practice guidelines:the diagnosis and management of patients with primary biliary cholangitis[J].J Hepatol, 2017, 67 (1) :145-172.

[4]DAHLQVIST G, GAOUAR F, CARRAT F, et al.Large-scale characterization study of patients with antimitochondrial antibodies but nonestablished primary biliary cholangitis[J].Hepatology, 2017, 65 (1) :152-163.

[5]CARBONE M, SHARP SJ, FLACK S, et al.The UK-PBC risk scores:derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis[J].Hepatology, 2016, 63 (3) :930-950.

[6]LAMMERS WJ, HIRSCHFIELD GM, CORPECHOT C, et al.Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy[J].Gastroenterology, 2015, 149 (7) :1804-1812.

[7]YANG F, YANG Y, WANG Q, et al.The risk predictive values of UK-PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis:the additional effect of anti-gp210[J].Aliment Pharmacol Ther, 2017, 45 (5) :733-743.

[8]YANG F, YANG Y, TANG R, et al.Editorial:scoring systems in primary biliary cholangitis-time to make a move.Authors'reply[J].Aliment Pharmacol Ther, 2017, 45 (8) :1164-1165.

[9]NEVENS F, ANDREONE P, MAZZELLA G, et al.A placebo-controlled trial of obeticholic acid in primary biliary cholangitis[J].N Engl J Med, 2016, 375 (7) :631-643.

[10]SAMUR S, KLEBANOFF M, BANKEN R, et al.Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis[J].Hepatology, 2017, 65 (3) :920-928.

[11]WANG Q, YANG F, MIAO Q, et al.The clinical phenotypes of autoimmune hepatitis:a comprehensive review[J].J Autoimmun, 2016, 66:98-107.

[12]YANG F, WANG Q, WANG Z, et al.The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis[J].Clin Rev Allergy Immunol, 2016, 50 (1) :114-123.

[13]Chinese Society of Hepatology, Chinese Medical Association;Chinese Society of Gastroenterology, Chinese Medical Association;Chinese Society of Infectious Diseases, Chinese Medical Association.Consensus on the diagnosis and management of primary biliary cirrhosis (cholangitis) (2015) [J].J Clin Hepatol, 2015, 31 (12) :1980-1988. (in Chinese) 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会.原发性胆汁性肝硬化 (又名原发性胆汁性胆管炎) 诊断和治疗共识 (2015) [J].临床肝胆病杂志, 2015, 31 (12) :1980-1988.

施引文献

资源附件(0)

访问统计